目的　探讨肝脏肿瘤患者血清 TGF- α、s ICAM- 1检测的临床意义。方法　采用免疫放射法和 EL ISA法分别检测 6 4例肝癌、4 2例良性肝肿瘤和 2 0例正常对照者血清 TGF-α及 s ICAM- 1的水平。结果　肝癌组血清 TGF-α、s ICAM- 1的水平均明显高于良性组及对照组 (P<0 .0 1) ,良性组与对照组相比较无显著性差异 (P>0 .0 5 )。血清 TGF-α、s ICAM- 1对肝癌诊断的灵敏度分别为 82 .8%、84 .3% ,优于 AFP,三者联合检测灵敏度和特异性可达 96 .8%和10 0 %。结论　血清 TGF- α、s ICAM- 1可作为肝癌的诊断指标 ,与 AFP联合检测对肝肿瘤的鉴别诊断具有重要临床意义。 Objective To investigate the clinical significance of serum TGF-α and s ICAM-1 in patients with liver cancer. Methods The levels of serum TGF-α and s ICAM-1 in 64 cases of hepatocellular carcinoma, 42 cases of benign hepatic tumor and 20 cases of normal control were detected by immunoradiometry and ELISA. Results The levels of serum TGF-α and ICAM-1 in HCC were significantly higher than those in benign and control groups (P <0.01), but there was no significant difference between benign and control groups (P> 0.05) ). The sensitivity of serum TGF-αand sICAM-1 to hepatocellular carcinoma were 82.8% and 84.3%, respectively, which were better than AFP. The sensitivity and specificity of combined detection of TGF-α and sICAM-1 were 96.8% and 100% respectively. Conclusion The serum levels of TGF-α and s ICAM-1 can be used as the diagnostic indicators of liver cancer. Combined with AFP detection, it has important clinical significance in the differential diagnosis of liver tumors.